Intrommune Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Intrommune Therapeutics's estimated annual revenue is currently $2.8M per year.(i)
  • Intrommune Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Intrommune Therapeutics has 18 Employees.(i)
  • Intrommune Therapeutics grew their employee count by -10% last year.

Intrommune Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder and CSOReveal Email/Phone
2
Founder & CEOReveal Email/Phone
3
Chief Regulatory OfficerReveal Email/Phone
4
Operations ManagerReveal Email/Phone
5
Manager, Administration & Social MediaReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Intrommune Therapeutics?

Intrommune Therapeutics is a specialty biopharmaceutical company located in New York, NY. Intrommune is developing a revolutionary new treatment platform for food allergies that is safe, effective and convenient. Intrommune's first product is a therapy for patients who suffer from peanut allergy. Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 9 million U.S. adults and 6 million U.S. children, who suffer from this life-altering condition.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$2.8M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Intrommune Therapeutics News

2022-03-30 - INT301 Continues to Meet Safety Goals in Phase 1 OMEGA ...

Intrommune Expands Study Scope to Explore MTD. NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M1813%N/A
#2
$0.8M1864%$68.7M
#3
$1.6M18-10%N/A
#4
$2.2M18-5%N/A
#5
$233.2M186%$3.2M